Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06526065 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 29, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.
Trial Details
NCT Number NCT06526065
Lead Sponsor University Medical Center Goettingen
Collaborators: Charite University, Berlin, Germany, Wuerzburg University Hospital, University Hospital Ulm, University of Leipzig, University Hospital Regensburg, University Hospital Freiburg, Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF), University of Kiel, University Hospital, Essen
Conditions DLBCL - Diffuse Large B Cell Lymphoma
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov